JP2003274996A - Method of avoiding influence of foreign substance - Google Patents
Method of avoiding influence of foreign substanceInfo
- Publication number
- JP2003274996A JP2003274996A JP2002086503A JP2002086503A JP2003274996A JP 2003274996 A JP2003274996 A JP 2003274996A JP 2002086503 A JP2002086503 A JP 2002086503A JP 2002086503 A JP2002086503 A JP 2002086503A JP 2003274996 A JP2003274996 A JP 2003274996A
- Authority
- JP
- Japan
- Prior art keywords
- reagent
- azide
- catalase
- oxidase
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 239000000126 substance Substances 0.000 title abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 48
- 102000016938 Catalase Human genes 0.000 claims abstract description 28
- 108010053835 Catalase Proteins 0.000 claims abstract description 28
- 238000006243 chemical reaction Methods 0.000 claims abstract description 26
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 24
- 150000001540 azides Chemical class 0.000 claims abstract description 21
- 102000003992 Peroxidases Human genes 0.000 claims abstract description 14
- 108040007629 peroxidase activity proteins Proteins 0.000 claims abstract description 14
- 102000004316 Oxidoreductases Human genes 0.000 claims abstract description 9
- 108090000854 Oxidoreductases Proteins 0.000 claims abstract description 9
- 238000001514 detection method Methods 0.000 claims abstract description 8
- 230000000694 effects Effects 0.000 claims description 17
- GUWHRJQTTVADPB-UHFFFAOYSA-N lithium azide Chemical group [Li+].[N-]=[N+]=[N-] GUWHRJQTTVADPB-UHFFFAOYSA-N 0.000 claims description 14
- 239000000356 contaminant Substances 0.000 claims description 7
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- -1 alkali metal salts Chemical class 0.000 claims description 2
- 238000005259 measurement Methods 0.000 abstract description 7
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 25
- 239000000523 sample Substances 0.000 description 18
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 16
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 14
- 229940109239 creatinine Drugs 0.000 description 13
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 12
- 239000012491 analyte Substances 0.000 description 11
- 229960003624 creatine Drugs 0.000 description 8
- 239000006046 creatine Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 101710188973 Catalase-4 Proteins 0.000 description 5
- 108010060059 Sarcosine Oxidase Proteins 0.000 description 5
- 102000008118 Sarcosine oxidase Human genes 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 239000004382 Amylase Substances 0.000 description 4
- 102000013142 Amylases Human genes 0.000 description 4
- 108010065511 Amylases Proteins 0.000 description 4
- 108010012029 Guanine Deaminase Proteins 0.000 description 4
- 102000013587 Guanine deaminase Human genes 0.000 description 4
- 235000019418 amylase Nutrition 0.000 description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 108010077078 Creatinase Proteins 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229940107700 pyruvic acid Drugs 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229940123748 Catalase inhibitor Drugs 0.000 description 2
- 108010089254 Cholesterol oxidase Proteins 0.000 description 2
- 108010066906 Creatininase Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 239000006173 Good's buffer Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- 108010042687 Pyruvate Oxidase Proteins 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010092464 Urate Oxidase Proteins 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 229940043230 sarcosine Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- 108010024957 Ascorbate Oxidase Proteins 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 239000007992 BES buffer Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000008000 CHES buffer Substances 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000057621 Glycerol kinases Human genes 0.000 description 1
- 108700016170 Glycerol kinases Proteins 0.000 description 1
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108010008604 L-alpha-glycerol-phosphate oxidase Proteins 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000191936 Micrococcus sp. Species 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 description 1
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000021336 beef liver Nutrition 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 108010090622 glycerol oxidase Proteins 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000001008 quinone-imine dye Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、夾雑物質による影
響回避方法に関する。詳しくは、試料中に存在する分析
対象物から過酸化水素を生成させ、生成した過酸化水素
を測定することにより分析対象物を検出するにあたり、
分析対象物以外の物質(妨害物質)に由来する過酸化水
素をカタラーゼを用いて消去した後、分析対象物を検出
する際にカタラーゼ活性を阻害する方法に関する。TECHNICAL FIELD The present invention relates to a method for avoiding the influence of contaminants. Specifically, when hydrogen peroxide is produced from the analyte present in the sample and the analyte is detected by measuring the produced hydrogen peroxide,
The present invention relates to a method for inhibiting catalase activity when detecting an analyte after eliminating hydrogen peroxide derived from a substance (interfering substance) other than the analyte using catalase.
【0002】[0002]
【従来の技術】体液などの試料中の分析対象物を酵素を
用いて検出する場合、その検出反応系は脱水素酵素を補
酵素であるNAD(P)Hとを共役させる反応系と、酸
化酵素とペルオキシダーゼを共役させる過酸化水素測定
系が一般的に多い。後者は分析対象物またはその反応生
成物に酸化酵素を作用させ、生成する過酸化水素をペル
オキシダーゼと色原体により、例えばキノンイミン色素
に変え、該色素を吸光度測定して比色定量する方法であ
る。また、分析対象物を検出する場合、その分析対象物
に直接、酸化酵素を作用させる場合もあるが、多くの場
合は、酸化酵素およびペルオキシダーゼの他に、更に1
種類以上の他の酵素を必要とする。2. Description of the Related Art When an analyte in a sample such as body fluid is detected using an enzyme, the detection reaction system includes a reaction system for coupling a dehydrogenase with NAD (P) H, which is a coenzyme, and an oxidation reaction. Generally, there are many hydrogen peroxide measurement systems that couple an enzyme with peroxidase. The latter is a method in which an oxidase is allowed to act on an analyte or a reaction product thereof, and hydrogen peroxide produced is converted to a quinoneimine dye, for example, by a peroxidase and a chromogen, and the dye is subjected to absorbance measurement for colorimetric determination. . When detecting an analyte, the oxidase may act directly on the analyte, but in many cases, in addition to the oxidase and peroxidase, 1
Requires more than one type of other enzyme.
【0003】分析対象物に酸化酵素の他に1種類以上の
他の酵素を必要とする例として、トリグリセリド、クレ
アチニン、クレアチン、遊離コレステロール、コレステ
ロールエステル、リン脂質、無機リン、アミラーゼ、G
OT、GTP、シアル酸、グアナーゼなどが挙げられ
る。[0003] Examples of requiring one or more kinds of other enzymes in addition to the oxidase as an analyte include triglyceride, creatinine, creatine, free cholesterol, cholesterol ester, phospholipid, inorganic phosphorus, amylase, G
Examples include OT, GTP, sialic acid and guanase.
【0004】近年、臨床検査試薬の精度向上の為に生体
試料中の夾雑物質による影響回避が試薬性能上重要な要
素となっている。これらの分析対象物を含む試料、例え
ば体液中には上記酵素反応系に関与する内因性の物質が
存在し、目的の分析対象物の測定に正の誤差を生じるこ
とが問題となる。例えばトリグリセリドを測定する場
合、遊離グリセロール、クレアチニンを測定する場合、
クレアチンおよびザルコシン、エステル型コレステロー
ルを測定する場合、遊離コレステロール、リン脂質を測
定する場合、コリン、無機リンを測定する場合、ヒポキ
サンチン、アミラーゼ活性を測定する場合、グルコー
ス、GOTまたはGTP活性を測定する場合、ピルビン
酸、シアル酸を測定する場合、ピルビン酸、グアナーゼ
を測定する場合、尿酸などが例示される。In recent years, in order to improve the accuracy of clinical test reagents, avoiding the influence of contaminants in biological samples has become an important factor in reagent performance. There is a problem that an endogenous substance involved in the above-mentioned enzyme reaction system is present in a sample containing these analytes, for example, body fluid, and a positive error occurs in the measurement of the objective analyte. For example, when measuring triglyceride, when measuring free glycerol and creatinine,
When measuring creatine and sarcosine and ester type cholesterol, when measuring free cholesterol and phospholipid, when measuring choline and inorganic phosphorus, when measuring hypoxanthine and amylase activity, when measuring glucose, GOT or GTP activity Examples include pyruvic acid and sialic acid, pyruvic acid and guanase, and uric acid.
【0005】従来、問題点の対策として実施されてきた
方法は、1つは内因性の夾雑物質を検体ブランクとして
差し引く方法がある。この方法は誤差を防ぐことはでき
るが、検体ブランクとして専用の試薬が別に必要とな
り、更にその為の測定操作が加わり、煩雑な方法で自動
分析機等への適用性が低く実用的ではない。Conventionally, one of the methods that have been carried out as a measure against the problem is a method of subtracting an endogenous contaminant as a sample blank. Although this method can prevent an error, it requires a special reagent as a sample blank, requires additional measurement operation, and is not practical due to its low applicability to automatic analyzers and the like.
【0006】別の方法として夾雑物質に特異的な酸化酵
素を作用させることによって生成させた過酸化水素をカ
タラーゼによって無色の物質に変換することで消去した
後、本反応に必要のないカタラーゼをカタラーゼ阻害剤
によって活性を阻害する方法が知られている。[0006] As another method, hydrogen peroxide generated by the action of a specific oxidase on a contaminant is converted into a colorless substance by catalase to eliminate it, and then catalase which is unnecessary for this reaction is removed. Methods of inhibiting activity with inhibitors are known.
【0007】例えばクレアチニン測定では、クレアチニ
ンにクレアチニンアミドヒドロラーゼが作用して生成す
るクレアチンも生体内に存在するのでクレアチニンを測
定する場合、あらかじめクレアチンを消去しておく必要
性が生じる。内因性のクレアチンを消去するために、カ
タラーゼを用いた2試薬系のクレアチニン測定用試薬が
知られている(特公平4-34400号公報) 。For example, in the measurement of creatinine, creatine produced by the action of creatinine amidohydrolase on creatinine also exists in the living body, and therefore, when creatinine is measured, it is necessary to delete creatine in advance. In order to eliminate endogenous creatine, a two-reagent system creatinine measuring reagent using catalase is known (Japanese Patent Publication No. 4-34400).
【0008】クレアチニン測定試薬としては、例えば下
記組成を有するものが挙げられる。試薬R1:クレアチ
ンアミジノヒドロラーゼ、ザルコシンオキシダーゼ、カ
タラーゼ、試薬R2:クレアチニンアミドヒドロラー
ゼ、ペルオキシダーゼ、色原体。Examples of creatinine measuring reagents include those having the following composition. Reagent R1: creatine amidinohydrolase, sarcosine oxidase, catalase, reagent R2: creatinine amide hydrolase, peroxidase, chromogen.
【0009】つまり、試薬R1に用いる第1酵素反応
で、試料中のクレアチンをクレアチンアミジノヒドロラ
ーゼ、ザルコシンオキシダーゼ、カタラーゼの反応によ
り無色の物質に変換して消去する。That is, in the first enzymatic reaction used for the reagent R1, creatine in the sample is converted into a colorless substance by the reaction of creatine amidinohydrolase, sarcosine oxidase and catalase, and erased.
【0010】次いで第2酵素反応として、試薬R2を試
料および試薬R1の系に添加して、クレアチニンアミド
ヒドロラーゼ、クレアチンアミジノヒドロラーゼ、ザル
コシンオキシダーゼ、色原体およびペルオキシダーゼの
反応により、試料中のクレアチニンから有色物質を生成
し、該物質を比色定量する。Then, as a second enzymatic reaction, the reagent R2 was added to the system of the sample and the reagent R1 to react the creatinine in the sample with creatinine amidohydrolase, creatine amidinohydrolase, sarcosine oxidase, chromogen and peroxidase. A colored material is produced and the material is colorimetrically determined.
【0011】第2酵素反応に共存するカタラーゼは、そ
のカタラーゼ阻害剤を添加することにより該酵素反応を
ブロックできる。クレアチニンと同様にトリグリセリ
ド、無機リン測定などの検出においても同様に分析対象
物以外に由来する過酸化水素の消去が必要とされる。Catalase that coexists in the second enzymatic reaction can be blocked by adding the catalase inhibitor. Similarly to creatinine, elimination of hydrogen peroxide derived from other than the analyte is also required in detection such as triglyceride and inorganic phosphorus measurement.
【0012】上記のカタラーゼ阻害剤としては、従来ア
ジ化ナトリウムが汎用されてきた。Sodium azide has heretofore been widely used as the above-mentioned catalase inhibitor.
【0013】[0013]
【発明が解決しようとする課題】アジ化物は金属塩を形
成することによって爆発性を有することが知られてお
り、試液中の含有量は少ない事が望ましい。また、試液
の調製時に酸性域において有毒なアジ化ガスが発生する
ことが知られており、含有量は少ない事が望ましい。ま
た、アジ化ナトリウムは測定反応には直接関わらない物
質であるが、生体試料には多くの物質が混合しているた
め、試料中の未知の成分とアジ化ナトリウムまたは原料
としてのアジ化ナトリウム製剤中の不純物などとの非特
異反応の可能性も考えられ、この点からも試液中の含有
量は少ない事が望ましい。It is known that an azide has an explosive property by forming a metal salt, and it is desirable that its content in the reagent solution is small. Further, it is known that a toxic azide gas is generated in an acidic region during preparation of a test solution, and it is desirable that the content is small. Also, sodium azide is a substance that is not directly involved in the measurement reaction, but since many substances are mixed in biological samples, unknown components in the sample and sodium azide or sodium azide preparations as raw materials There is a possibility of non-specific reaction with impurities in the solution. From this point as well, it is desirable that the content in the reagent solution is low.
【0014】[0014]
【課題を解決するための手段】本発明者らは、上記目的
を達成するために種々検討した結果、アジ化リチウムが
アジ化ナトリウムよりも高いカタラーゼ活性阻害能を持
つことを見いだし、これにより、アジ化リチウムを用い
ることで試薬中のアジ化物を低量に抑えることが可能な
ことを見いだし、本発明を完成した。As a result of various studies to achieve the above object, the present inventors have found that lithium azide has a higher ability to inhibit catalase activity than sodium azide. The inventors have found that the amount of azide in a reagent can be suppressed to a low level by using lithium azide, and have completed the present invention.
【0015】すなわち本発明は、
(1)検出反応系として酸化酵素とペルオキシダーゼを
共役させる過酸化水素測定系を経由する生体成分の測定
に際して、試薬が2種類以上の溶液から構成され、その
反応液への添加が特定の順序で行われるよう規定されて
いる測定方法において、第1試薬にカタラーゼを含み、
検出反応時にカタラーゼ反応を阻害する方法において、
5〜500mg/Lのアジ化物を用いることを特徴とす
る、夾雑物質による影響回避方法。
(2)アジ化物が1価のアルカリ金属塩より選ばれる少
なくとも1種のアジ化物を用いた(1)記載の方法。
(3)アジ化物がアジ化リチウムである(2)記載の方
法。
(4)試薬のpHが5〜10である(1)〜(3)記載
の方法。
である。That is, the present invention is as follows: (1) When a biological component is measured via a hydrogen peroxide measuring system that couples an oxidase and a peroxidase as a detection reaction system, the reagent is composed of two or more kinds of solutions, and the reaction solution In a measurement method that is specified to be added in a specific order, the first reagent contains catalase,
In the method of inhibiting the catalase reaction during the detection reaction,
A method for avoiding the influence of contaminants, which comprises using 5-500 mg / L of azide. (2) The method according to (1), wherein the azide is at least one azide selected from monovalent alkali metal salts. (3) The method according to (2), wherein the azide is lithium azide. (4) The method according to (1) to (3), wherein the pH of the reagent is 5 to 10. Is.
【0016】[0016]
【発明の実施の形態】本発明において「カタラーゼ活性
の阻害」とは、本反応において生成された過酸化水素を
カタラーゼの反応によって消去されないことを意味す
る。BEST MODE FOR CARRYING OUT THE INVENTION In the present invention, "inhibition of catalase activity" means that hydrogen peroxide produced in this reaction is not eliminated by the reaction of catalase.
【0017】本発明において「夾雑物質」とは還元物質
であるアスコルビン酸や中性脂肪を測定する場合の遊離
グリセロール、クレアチニンを測定する場合のクレアチ
ン及びザルコシン、エステル型コレステロールを測定す
る場合の遊離コレステロール、アミラーゼ活性を測定す
る場合のグルコース、シアル酸を測定する場合のピルビ
ン酸、グアナーゼ活性を測定する場合の尿酸等がそれで
ある。In the present invention, "contaminant" means free glycerol when measuring ascorbic acid or neutral fat which is a reducing substance, creatine and sarcosine when measuring creatinine, and free cholesterol when measuring ester cholesterol. , Glucose for measuring amylase activity, pyruvic acid for measuring sialic acid, and uric acid for measuring guanase activity.
【0018】この発明において「酸化酵素」とは、アス
コルビン酸オキシダーゼ、グリセロールオキシダーゼ、
グリセロリン酸オキシダーゼ、ザルコシンオキシダー
ゼ、コレステロールオキシダーゼ、グルコースオキシダ
ーゼ、ピルビン酸オキシダーゼ、ウリカーゼ等があり、
過酸化水素を発生する酸化酵素であれば、いかなる起源
のものでも良い。In the present invention, "oxidizing enzyme" means ascorbate oxidase, glycerol oxidase,
There are glycerophosphate oxidase, sarcosine oxidase, cholesterol oxidase, glucose oxidase, pyruvate oxidase, uricase, etc.,
Any source may be used as long as it is an oxidase that generates hydrogen peroxide.
【0019】この発明において使用するカタラーゼは、
いかなる起源のものでも良い。例えば肝臓、赤血球、胃
等に含まれる動物由来のものや、ミクロコッカス属、ア
スペルギルス属等の微生物に含まれるものなどが挙げら
れる。従来から牛の肝臓由来の酵素が多く使用されてい
る。上記のほか、他の動物や微生物由来のカタラーゼを
用いることが可能である。The catalase used in this invention is
It can be of any origin. Examples include animal-derived substances contained in liver, red blood cells, stomach, etc., and those contained in microorganisms such as Micrococcus sp., Aspergillus sp. Conventionally, many enzymes derived from bovine liver have been used. In addition to the above, it is possible to use catalase derived from other animals or microorganisms.
【0020】この発明において使用する、カタラーゼ活
性阻害剤はアジ化物である。アジ化物としては、1価の
アルカリ金属との化合物であればよく、アジ化ナトリウ
ム、アジ化リチウム等が挙げられるが、好ましくはアジ
化リチウムを用いたほうが良い。The catalase activity inhibitor used in the present invention is an azide. The azide may be a compound with a monovalent alkali metal, and examples thereof include sodium azide and lithium azide, but it is preferable to use lithium azide.
【0021】アジ化物の使用濃度として、5〜500m
g/dLの範囲でカタラーゼ活性阻害能を認めるが、好
ましくは5〜100mg/dLが良く、さらに好ましく
は10〜50mg/dLの範囲で使用するのが良い。The concentration of azide used is 5 to 500 m.
The ability to inhibit catalase activity is recognized in the range of g / dL, but it is preferably 5 to 100 mg / dL, and more preferably 10 to 50 mg / dL.
【0022】緩衝液としては特に制限は無く、その反応
系に適当なpHを保つことが出来るならば、いかなる種
類のものでも良い。通常用いられる緩衝液としてトリス
緩衝液、リン酸緩衝液、GOOD緩衝液などが挙げられ
る。なかでも、トリス緩衝液、リン酸緩衝液は濃度、温
度によってpHが変動しやすいが、安価であるという利
点がある。一方、GOOD緩衝液にはMES、Bis−
Tris、ACES、BES、MOPS、PIPES、
TES、HEPES、Tricine、Bicine、
POPSO、TAPS、CHES、CAPSなどが例示
される。The buffer solution is not particularly limited and may be of any type as long as it can maintain a pH suitable for the reaction system. Examples of commonly used buffers include Tris buffer, phosphate buffer, GOOD buffer and the like. Among them, the Tris buffer solution and the phosphate buffer solution have the advantage of being inexpensive, although the pH is likely to change depending on the concentration and temperature. On the other hand, the GOOD buffer contains MES and Bis-
Tris, ACES, BES, MOPS, PIPES,
TES, HEPES, Tricine, Bicine,
Examples include POPSO, TAPS, CHES, CAPS and the like.
【0023】使用するpHとしては、特に限定されるも
のではないが、通常の酵素反応に使用するpH5〜10
の範囲であれば良い。好ましくは、pH6〜8の範囲で
使用するのが良い。The pH to be used is not particularly limited, but the pH used for ordinary enzyme reaction is 5-10.
It should be in the range of. It is preferable to use it within a pH range of 6-8.
【0024】次に具体的な基質又は酵素活性の定量方法
について説明する。Next, a specific method for quantifying the substrate or enzyme activity will be described.
【0025】中性脂肪(トリグリセライド)の定量
試料に第1試薬を加えた後、第2試薬を加えて生じた吸
光度より比色定量する。
第1試薬
グリセロールキナーゼ
グリセロールリン酸オキシダーゼ
カタラーゼ
アデノシン3リン酸
4アミノアンチピリン
第2試薬
リポプロテインリパーゼ
ペルオキシダーゼ
アジ化リチウム
DEA(ジエチルアニリン)
反応系を式1に示す。After the first reagent is added to the quantitative sample of neutral fat (triglyceride), the second reagent is added to the sample and the resulting absorbance is colorimetrically determined. 1st reagent glycerol kinase glycerol phosphate oxidase catalase adenosine 3 phosphate 4 aminoantipyrine 2nd reagent lipoprotein lipase peroxidase lithium azide DEA (diethylaniline) The reaction system is shown in Formula 1.
【0026】[0026]
【式1】 [Formula 1]
【0027】クレアチニンの定量
試料に第1試薬を加えた後、第2試薬を加えて生じた吸
光度より比色定量する。
第1試薬
クレアチンアミジノヒドラーゼ
ザルコシンオキシダーゼ
カタラーゼ
4アミノアンチピリン
第2試薬
クレアチニンアミジドヒドラーゼ
ペルオキシダーゼ
アジ化リチウム
DEA(ジエチルアニリン)
反応系を式2に示す。After the addition of the first reagent to the quantitative sample of creatinine, the second reagent is added, and the colorimetric determination is carried out from the resulting absorbance. First reagent creatine amidinohydrase sarcosine oxidase catalase 4 aminoantipyrine 2nd reagent creatinine amididohydrase peroxidase lithium azide DEA (diethylaniline) The reaction system is shown in Formula 2.
【0028】[0028]
【式2】 [Formula 2]
【0029】エステル型コレステロールの定量
試料に第1試薬を加えた後、第2試薬を加えて生じた吸
光度より比色定量する。
第1試薬
コレステロールオキシダーゼ
カタラーゼ
4アミノアンチピリン
第2試薬
コレステロールエステラーゼ
ペルオキシダーゼ
アジ化リチウム
DEA(ジエチルアニリン)
反応系を式3に示す。After the first reagent was added to the quantitative sample of ester cholesterol, the second reagent was added to the sample, and colorimetric determination was carried out from the resulting absorbance. First reagent cholesterol oxidase catalase 4 aminoantipyrine Second reagent cholesterol esterase peroxidase lithium azide DEA (diethylaniline) The reaction system is shown in Formula 3.
【0030】[0030]
【式3】 [Formula 3]
【0031】アミラーゼの定量
試料に第1試薬を加えた後、第2試薬を加えて生じた吸
光度より比色定量する。
第1試薬
グルコースオキシダーゼ
β−グルコシダーゼ
カタラーゼ
4アミノアンチピリン
第2試薬
デンプン(基質)
ペルオキシダーゼ
アジ化リチウム
DEA(ジエチルアニリン)
反応系を式4に示す。After the first reagent is added to the amylase quantitative sample, the second reagent is added to the sample and the resulting absorbance is colorimetrically determined. First Reagent Glucose Oxidase β-Glucosidase Catalase 4 Aminoantipyrine Second Reagent Starch (Substrate) Peroxidase Lithium Azide DEA (Diethylaniline) The reaction system is shown in Formula 4.
【0032】[0032]
【式4】 [Formula 4]
【0033】シアル酸の定量
試料に第1試薬を加えた後、第2試薬を加えて生じた吸
光度より比色定量する。
第1試薬
ピルビン酸オキシダーゼ
カタラーゼ
4アミノアンチピリン
第2試薬
ノイラミンダーゼ
ペルオキシダーゼ
アジ化リチウム
DEA(ジエチルアニリン)
反応系を式5に示す。Quantitative determination of sialic acid After the first reagent is added to the sample, the second reagent is added to carry out colorimetric quantification from the resulting absorbance. First reagent pyruvate oxidase catalase 4 aminoantipyrine Second reagent neuraminidase peroxidase lithium azide DEA (diethylaniline) The reaction system is shown in Formula 5.
【0034】[0034]
【式5】 [Formula 5]
【0035】グアナーゼの定量
試料に第1試薬を加えた後、第2試薬を加えて生じた吸
光度より比色定量する。
第1試薬
キサンチンオキシダーゼ
ウリカーゼ
カタラーゼ
4アミノアンチピリン
第2試薬
グアニン(基質)
ペルオキシダーゼ
アジ化リチウム
DEA(ジエチルアニリン)
反応系を式6に示す。After the addition of the first reagent to the quantitative sample of guanase, the second reagent is added to perform the colorimetric quantification based on the resulting absorbance. First Reagent Xanthine Oxidase Uricase Catalase 4 Aminoantipyrine Second Reagent Guanine (Substrate) Peroxidase Lithium Azide DEA (Diethylaniline) The reaction system is shown in Formula 6.
【0036】[0036]
【式6】 [Formula 6]
【0037】[0037]
【実施例】以下、本発明を実施例により具体的に説明す
る。なお、本発明は実施例により特に限定されるもので
はない。EXAMPLES The present invention will be specifically described below with reference to examples. The present invention is not particularly limited to the examples.
【0038】(実施例1)カタラーゼを含有する水溶液
にアジ化物を5〜1000mg/dLとなるように添加
した時のカタラーゼ活性阻害率(アジ化物無添加の時の
活性値を0%とした場合の相対活性率)を検討した。な
お、カタラーゼ活性測定方法はチタン呈色法を用いて実
施した。(Example 1) Catalase activity inhibition rate when azide was added to an aqueous solution containing catalase at 5 to 1000 mg / dL (when the activity value without addition of azide was 0%) Relative activity ratio) was examined. The method for measuring catalase activity was performed using the titanium coloration method.
【0039】(試薬調整) PIPES緩衝液(pH7.0) 50mM カタラーゼ(牛肝臓由来) 1000U/mL アジ化物 5〜1000mg/dL(Reagent preparation) PIPES buffer (pH 7.0) 50 mM Catalase (from beef liver) 1000 U / mL Azide 5-1000 mg / dL
【0040】[0040]
【表1】 [Table 1]
【0041】(結果)表1に示す。すべての添加濃度に
おいて、アジ化リチウムの方がカタラーゼ活性の阻害率
が有意に高いことが分かる。(Results) The results are shown in Table 1. It can be seen that the inhibition rate of catalase activity is significantly higher in lithium azide at all addition concentrations.
【0042】[0042]
【発明の効果】本発明においては、アジ化物としてアジ
化リチウムを添加することによって、アジ化ナトリウム
よりも少量でカタラーゼ活性の阻害ができる。このた
め、危険物質であるアジ化物の含有量を少なくすること
が可能となり、また、試薬調製時に問題となるアジ化ガ
スの発生頻度をも低減させることが可能である。In the present invention, by adding lithium azide as an azide, the catalase activity can be inhibited with a smaller amount than sodium azide. Therefore, it is possible to reduce the content of the azide, which is a dangerous substance, and it is also possible to reduce the frequency of generation of the azide gas, which is a problem during reagent preparation.
───────────────────────────────────────────────────── フロントページの続き Fターム(参考) 2G045 AA28 BA01 BB44 BB51 DA20 DA31 DA42 DA43 DA61 DA69 DA70 DB21 FB01 GC10 GC12 4B063 QA01 QQ61 QR02 QR03 QS20 QS36 QX01 ─────────────────────────────────────────────────── ─── Continued front page F term (reference) 2G045 AA28 BA01 BB44 BB51 DA20 DA31 DA42 DA43 DA61 DA69 DA70 DB21 FB01 GC10 GC12 4B063 QA01 QQ61 QR02 QR03 QS20 QS36 QX01
Claims (4)
ーゼを共役させる過酸化水素測定系を経由する生体成分
の測定に際して、試薬が2種類以上の溶液から構成さ
れ、その反応液への添加が特定の順序で行われるよう規
定されている測定方法において、第1試薬にカタラーゼ
を含み、検出反応時にカタラーゼ反応を阻害する方法に
おいて、5〜500mg/Lのアジ化物を用いることを
特徴とする、夾雑物質による影響回避方法。1. When measuring a biological component via a hydrogen peroxide measuring system that couples an oxidase and a peroxidase as a detection reaction system, the reagent is composed of two or more kinds of solutions, and the addition to the reaction solution is specific. Contaminant, characterized by using 5-500 mg / L of azide in the method of assaying to be performed in order, wherein the first reagent contains catalase and the catalase reaction is inhibited during the detection reaction. How to avoid the effects.
れる少なくとも1種のアジ化物を用いた請求項1記載の
方法。2. The method according to claim 1, wherein the azide is at least one azide selected from monovalent alkali metal salts.
記載の方法。3. The azide is lithium azide.
The method described.
記載の方法。4. The pH of the reagent is 5-10.
The method described.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002086503A JP4081709B2 (en) | 2002-03-26 | 2002-03-26 | How to avoid the effects of contaminants |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002086503A JP4081709B2 (en) | 2002-03-26 | 2002-03-26 | How to avoid the effects of contaminants |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2003274996A true JP2003274996A (en) | 2003-09-30 |
JP4081709B2 JP4081709B2 (en) | 2008-04-30 |
Family
ID=29207290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002086503A Expired - Fee Related JP4081709B2 (en) | 2002-03-26 | 2002-03-26 | How to avoid the effects of contaminants |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4081709B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009035015A1 (en) * | 2007-09-12 | 2009-03-19 | Denka Seiken Co., Ltd. | Method of reducing measurement error caused by catalase inhibition by azide |
ITTS20080010A1 (en) * | 2008-11-19 | 2010-05-20 | Eurosen S R L | ELIMINATION OF POLYPHENOLS FROM ANALYTICAL SAMPLES |
WO2023190087A1 (en) * | 2022-03-31 | 2023-10-05 | 東洋紡株式会社 | Enhacement of accuracy when measuring high-creatinine-value specimen |
-
2002
- 2002-03-26 JP JP2002086503A patent/JP4081709B2/en not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009035015A1 (en) * | 2007-09-12 | 2009-03-19 | Denka Seiken Co., Ltd. | Method of reducing measurement error caused by catalase inhibition by azide |
JP2009065883A (en) * | 2007-09-12 | 2009-04-02 | Denka Seiken Co Ltd | Method for reducing measurement error due to catalase inhibition by azide |
CN101809163A (en) * | 2007-09-12 | 2010-08-18 | 电化生研株式会社 | Method of reducing measurement error caused by catalase inhibition by azide |
CN101809163B (en) * | 2007-09-12 | 2015-05-13 | 电化生研株式会社 | Method of reducing measurement error caused by catalase inhibition by azide |
KR101578790B1 (en) | 2007-09-12 | 2015-12-18 | 덴카 세이켄 가부시키가이샤 | Method of reducing measurement error caused by catalase inhibition by azide |
US10415077B2 (en) | 2007-09-12 | 2019-09-17 | Denka Seiken Co., Ltd. | Method of reducing measurement error caused by catalase inhibition by azide |
ITTS20080010A1 (en) * | 2008-11-19 | 2010-05-20 | Eurosen S R L | ELIMINATION OF POLYPHENOLS FROM ANALYTICAL SAMPLES |
WO2023190087A1 (en) * | 2022-03-31 | 2023-10-05 | 東洋紡株式会社 | Enhacement of accuracy when measuring high-creatinine-value specimen |
Also Published As
Publication number | Publication date |
---|---|
JP4081709B2 (en) | 2008-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0577399B2 (en) | ||
LV11068B (en) | Determination of ions in fluids | |
CS228127B2 (en) | Reagencni cinidlo | |
Noma et al. | Polarographic method for rapid microdetermination of cholesterol with cholesterol esterase and cholesterol oxidase. | |
JPH11504808A (en) | Measurement of glycated protein | |
EP1598426B1 (en) | Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same | |
JP2854995B2 (en) | Uric acid measurement reagent composition | |
US5962248A (en) | Quantitative determination method for chloride ions | |
EP0657545B1 (en) | Assay method for biological components | |
JP4081709B2 (en) | How to avoid the effects of contaminants | |
JP5216968B2 (en) | Method and reagent for measuring substance to be measured in sample using tetrazolium compound as chromogen, method for inhibiting non-specific color development, and non-specific color development inhibitor | |
JPH02104298A (en) | Quantification of 1,5-anhydroglucitol | |
JP3695596B2 (en) | Biological component measurement method and reagent composition for measurement | |
JP2008197077A (en) | Method and reagent for measuring object substance to be measured in sample, method for inhibiting nonspecific coloring, and nonspecific coloring inhibitor | |
JPH04200396A (en) | High-sensitivity enzymatic determination of hydrogen peroxide and reagent therefor | |
JPH0434400B2 (en) | ||
JP2002238598A (en) | Composition for measuring calcium ion and measuring method | |
JP3522307B2 (en) | Liquid reagent composition for measuring inorganic phosphorus | |
WO1990001067A1 (en) | Reagent for use in ld-1 assay | |
JP2007236234A (en) | Method for reducing measurement error due to catalase inhibition by azide | |
JP3670687B2 (en) | Method for measuring 1,5-anhydroglucitol | |
JP3868214B2 (en) | Stabilization of liquid catalase | |
JP2643205B2 (en) | Highly sensitive colorimetric method | |
EP0464388A1 (en) | Detection assays having chromogenic and nonchromogenic, hypocromogenic, bathochromogenic or hypsochromogenic substrates | |
JP3936976B2 (en) | Enzymatic degradation of AMP |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071101 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071213 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071213 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080117 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080130 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 4081709 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110222 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110222 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120222 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130222 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130222 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140222 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |